Get the Stockscreener App
0.7723
5.81%
-0.0476
Pre-market:
.76
-0.0123
-1.59%
Creative Medical Technology Holdings Inc stock is traded at $0.7723, with a volume of 167.47K.
It is down -5.81% in the last 24 hours and down -12.73% over the past month.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
See More
Previous Close:
$0.8199
Open:
$0.8
24h Volume:
167.47K
Relative Volume:
1.67
Market Cap:
$5.86M
Revenue:
$3,000
Net Income/Loss:
$-5.76M
P/E Ratio:
-0.4181
EPS:
-1.8471
Net Cash Flow:
$-5.59M
1W Performance:
-10.24%
1M Performance:
-12.73%
6M Performance:
-66.71%
1Y Performance:
-79.18%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.7571
$0.88
52-Week Range:
$0.62
$6.25
Creative Medical Technology Holdings Inc Stock (CELZ) Company Profile
Name
Creative Medical Technology Holdings Inc
Sector
Industry
Phone
480-399-2822
Address
211 E. OSBORN RD., PHOENIX
Compare CELZ vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELZ
Creative Medical Technology Holdings Inc
|
0.7723 | 5.86M | 3,000 | -5.76M | -5.59M | -1.8471 |
VRTX
Vertex Pharmaceuticals Inc
|
498.50 | 126.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.30 | 90.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
778.36 | 80.14B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.30 | 51.46B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.52 | 41.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Creative Medical Technology Holdings Inc Stock (CELZ) Latest News
[SCHEDULE 13D] CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Major Shareholder Acquisition (>5%) - Stock Titan
Form 4 Creative Medical Technology Holdings Inc For: 25 September By Investing.com - Investing.com India
Form 4 Creative Medical Technology Holdings Inc For: 25 September By Investing.com - Investing.com Nigeria
Form 4 Creative Medical Technology Holdings Inc For: 25 September By Investing.com - Investing.com UK
[Form 4] CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Insider Trading Activity - Stock Titan
Creative Medical Technology Takes 80% Control of BioDefense in Cash-and-Stock Purchase - tradingview.com
Sunshine Biopharma, Inc. (SBFM) Stock Price, News, Quote & History - Yahoo Finance
Creative Medical Technology Holdings Stock Price Forecast. Should You Buy CELZ? - StockInvest.us
EPS Creative Health Tech’s Controlling Shareholder to Sell 22% Stake While Retaining Control - TipRanks
Creative Medical Technology Increases Authorized Shares to 100 Million - minichart.com.sg
Creative Medical Expands Authorized Shares and Warrant Exercise - TipRanks
Creative Medical Technology Holdings Inc. (CELZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Creative Medical Technology Holdings Inc. (CELZ) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
CELZ Holds Steady at $1.14 as Creative Medical Technology ConsolidatesChaikin Flow - dars.gov.et
Creative Medical Technology Holdings Inc. (CELZ) Peer Comparison – Compare with Others - Value Research
Creative Medical Technology Holdings Inc. (CELZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
Creative Medical completes Olastrocel trial enrollment as it sets sights on FDA Phase 3 path - Indian Pharma Post
Rest-Of-Europe Exosome Research Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
CELZ Looks 171.4% Overvalued on GF Value™ - GuruFocus
CELZ Looks 142.9% Overvalued on GF Value™ - GuruFocus
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning - The Manila Times
Creative Medical completes enrollment in chronic back pain trial - Investing.com
Creative Medical Technology Holdings Completes Enrollment And Treatment In FDA-Cleared ADAPT Clinical Trial Evaluating CELZ-201 / Olastrocel - marketscreener.com
Creative Medical finishes treating back-pain patients who use opioids - Stock Titan
Creative Medical Technology Holdings (NasdaqCM:CELZ) Stock Forecast & Analyst Predictions - Simply Wall Street
Creative (CELZ) EPS and Revenue Review: The EPS Result Is Below Expectation on the Day; Market Follow-Through: The Share Price Sheds 1.82% on the DayGuidance Accuracy Score - vinanet.vn
CELZ Q2 2026 Earnings: Wider Loss of -$0.41 per Share Misses Estimates; Stock Falls 1.6%EPS Consistency Score - vinanet.vn
CELZ Q2 2026 Earnings: EPS Miss of -$0.41 Reflects Pre-Revenue Pipeline InvestmentCFO Commentary Report - vinanet.vn
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
CELZ Q2 2026 Earnings: EPS Misses by 3.07% as Pre-Revenue Losses Persist; Stock Climbs 8.75%Cash Flow Report - vinanet.vn
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Benzinga
CELZ Jumps As New Diabetes Patent Fuels Volatile Rally - StocksToTrade
Creative Medical Technology | DEF 14A: Definitive information statements - Moomoo
Creative Medical net loss widens 22.5% to $1.51 million in Q2 2026 - Bitget
Creative Medical Technology Holdings, Inc. (CELZ) stock price, news, quote and history - Yahoo Finance Singapore
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. 2026: Revenue $0 Net income ($1.51M), EPS ($0.41) — 10-Q Summary - TradingView
Creative Medical Technology (NASDAQ: CELZ) Q2 loss, cash rises to $8.7M - Stock Titan
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Top Microcaps CELZ, PRSO, HCWC, TOON: Shorted Stocks to Watch in August 2026 - FinancialContent
Which stocks have an unusual volume on Friday? - ChartMill
Creative Medical Technology Holdings Inc (CELZ) Stock News Today - TradingKey
$Creative Medical Technology (CELZ.US)$ 小赚 - Moomoo
$Creative Medical Technology (CELZ.US)$ sky is so clear and the sun is out 🌄 - Moomoo
CELZ Stock Jumps As New Diabetes Patent Fuels Momentum - stockstotrade.com
Creative Medical Technology Holdings Inc (CELZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
$Creative Medical Technology (CELZ.US)$ 🫣 - Moomoo
Top Microcaps CELZ, PRSO, HCWC, TOON: Shorted Stocks to Watch in August 2026 - Barchart.com
$Creative Medical Technology (CELZ.US)$ double dipped😋 - Moomoo
12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com
Creative Medical Technology Holdings Inc Stock (CELZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.10%
5.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):